Lori J. Wirth

19.6k total citations · 4 hit papers
260 papers, 9.9k citations indexed

About

Lori J. Wirth is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lori J. Wirth has authored 260 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Oncology, 106 papers in Endocrinology, Diabetes and Metabolism and 76 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lori J. Wirth's work include Thyroid Cancer Diagnosis and Treatment (106 papers), Head and Neck Cancer Studies (68 papers) and Lung Cancer Treatments and Mutations (42 papers). Lori J. Wirth is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (106 papers), Head and Neck Cancer Studies (68 papers) and Lung Cancer Treatments and Mutations (42 papers). Lori J. Wirth collaborates with scholars based in United States, France and Australia. Lori J. Wirth's co-authors include Steven I. Sherman, Martin Schlumberger, Marcia S. Brose, Robert I. Haddad, Rossella Elisei, Manisha H. Shah, Marshall R. Posner, Bruce Robinson, Makoto Tahara and Corina E. Dutcus and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Lori J. Wirth

253 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

2015 1.4k citations Martin Schlumberger, Makoto Tahara et al. profile →
Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer

2025 16 citations Bruce Robinson, Lori J. Wirth et al. Thyroid profile →

Peers

Countries citing papers authored by Lori J. Wirth

Since Specialization

Citations

This map shows the geographic impact of Lori J. Wirth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori J. Wirth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori J. Wirth more than expected).

Fields of papers citing papers by Lori J. Wirth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori J. Wirth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori J. Wirth. The network helps show where Lori J. Wirth may publish in the future.

Co-authorship network of co-authors of Lori J. Wirth

This figure shows the co-authorship network connecting the top 25 collaborators of Lori J. Wirth. A scholar is included among the top collaborators of Lori J. Wirth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori J. Wirth. Lori J. Wirth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Emerging EGFR-Targeted Therapy in Head and Neck Cancer 2025 ·JAMA Oncology ·(unknown), Jong Seok Ahn, (unknown), Lori J. Wirth, Jong‐Chul Park	2
2	Familial Thyroid Cancers Syndromes 2025 ·Endocrinology and Metabolism Clinics of North America ·(unknown), Giuseppe Barbesino, Lori J. Wirth	1
3	Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC). 2024 ·Journal of Clinical Oncology ·Marcia S. Brose, Bruce Robinson, Lori J. Wirth, Jaume Capdevila, Jonathan Wadsley, Eric J. Sherman, Makoto Tahara, (unknown), Mimi I. Hu, Ming Gao, Fernanda Vaisman, (unknown), Boris K. Lin, Patricia Maeda, Adrienne M. Gilligan, Yan Lin, Nalin Payakachat, Julien Hadoux, Rossella Elisei	3
4	2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001 2023 ·Annals of Oncology ·Lori J. Wirth, Vivek Subbiah, Francis P. Worden, Benjamin Solomon, Bruce Robinson, Julien Hadoux, (unknown), (unknown), Barbara Deschler-Baier, (unknown), (unknown), (unknown), Patricia Maeda, Alexander Drilon, Philippe A. Cassier	3
5	Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit 2022 ·The Oncologist ·Lori J. Wirth, Cosimo Durante, Duncan J. Topliss, Eric Winquist, Eyal Robenshtok, Hiroyuki Iwasaki, Markus Luster, Rossella Elisei, Sophie Leboulleux, Makoto Tahara	28
6	MO3-4 Impact of baseline tumor size on overall survival in patients with RR-DTC treated with lenvatinib (SELECT) 2021 ·Annals of Oncology ·Naomi Kiyota, Makoto Tahara, Bruce Robinson, Martin Schlumberger, Steven I. Sherman, Sophie Leboulleux, Eun Kyung Lee, Takuya Suzuki, Min Ren, (unknown), Lori J. Wirth	3
7	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 2021 ·Journal of Clinical Oncology ·Lori J. Wirth, Marcia S. Brose, Eric J. Sherman, Lisa Licitra, Martin Schlumberger, Steven I. Sherman, Keith C. Bible, Bruce Robinson, Patrice Rodien, Yann Godbert, Christelle de la Fouchardière, Kate Newbold, Christopher M. Nutting, Soamnauth Misir, Ran Xie, (unknown), (unknown), Maria E. Cabanillas	83
8	Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization 2020 ·Modern Pathology ·Ying‐Hsia Chu, Lori J. Wirth, Alexander Farahani, Vânia Nosé, William C. Faquin, Dora Dias‐Santagata, Peter M. Sadow	76
9	Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model 2019 ·Cancer Immunology Immunotherapy ·Eiichi Ishida, Jina Lee, Jean S. Campbell, (unknown), Yukio Katori, Takenori Ogawa, (unknown), Anandaroop Mukhopadhyay, William C. Faquin, Derrick T. Lin, Lori J. Wirth, Robert H. Pierce, Sara I. Pai	7
10	Patients’ experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study 2018 ·Journal of Patient-Reported Outcomes ·Arnold Degboe, S.L. Knight, Katarina Halling, Andrew Trigg, (unknown), Natalie V. J. Aldhouse, Helen Kitchen, Lori J. Wirth, S.N. Rogers	10
11	88 ^th Annual Meeting of the American Thyroid Association 2018 ·Thyroid ·Gary L. Clayman, Ian D. Hay, Mimi I. Hu, Lori J. Wirth, (unknown), (unknown), (unknown), George J. Kahaly, Raymond S. Douglas, Robert J. Holt, (unknown), Julie Ball, Terry J. Smith, Seong‐Keun Yoo, Yoo Sung Song, Yongjung Park	6
12	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs 2017 ·Cancer Research ·Austin K. Mattox, Jina Lee, William H. Westra, Robert H. Pierce, Ronald Ghossein, William C. Faquin, Thomas Diefenbach, Luc G.T. Morris, Derrick T. Lin, Lori J. Wirth, (unknown), Eiichi Ishida, (unknown), (unknown), Yang Zeng, Huabiao Chen, Mark C. Poznansky, Neil M. Iyengar, Sara I. Pai	76
13	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study breakdown → 2017 ·Journal of Clinical Oncology ·Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad	497
14	Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib 2014 ·Clinical Cancer Research ·S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, Lori J. Wirth	265
15	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Jonathan H. Goldman, Sabine Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, (unknown), Hélène M. Faessel, (unknown), (unknown), Lee S. Rosen, Daniel W. Bowles	43
16	Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer 2014 ·Clinical Cancer Research ·Neil D. Gross, Julie E. Bauman, William E. Gooding, (unknown), Sufi M. Thomas, Lin Wang, Simion I. Chiosea, Brian L. Hood, Melanie S. Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Seungwon Kim, Athanassios Argiris, Lori J. Wirth, Marina N. Nikiforova, Jill M. Siegfried, Jennifer R. Grandis	39
17	Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial 2013 ·Cancer Prevention Research ·William B. Armstrong, Thomas H. Taylor, Ann R. Kennedy, Raymond J. Melrose, Diana V. Messadi, Mai Gu, Anh D. Le, Marjorie Perloff, Francisco Civantos, W. Jarrard Goodwin, Lori J. Wirth, Alexander Ross Kerr, Frank L. Meyskens	47
18	Cabozantinib in Progressive Medullary Thyroid Cancer breakdown → 2013 ·Journal of Clinical Oncology ·Rossella Elisei, Martin Schlumberger, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, В. С. Медведев, Michael C. Kreißl, Bruno Niederle, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman	850
19	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer 2009 ·Journal of Clinical Oncology ·Martin Schlumberger, Rossella Elisei, Lars Bastholt, Lori J. Wirth, Renato Martins, Laura D. Locati, Barbara Jarząb, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz, Michael Eschenberg, Yu-Nien Sun, Todd Juan, Daniel E. Stepan, Steven I. Sherman	257
20	A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions 2008 ·Cancer Prevention Research ·Lori J. Wirth, Jeffrey F. Krane, Yi Li, Megan Othus, Amy E. Moran, (unknown), Charles M. Norris, Laura A. Goguen, Marshall R. Posner, Robert I. Haddad, Monica M. Bertagnolli	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact